News & Updates

Adjuvant nivolumab confers no DFS benefit in resected NSCLC

In the treatment of patients with resected non–small cell lung cancer (NSCLC) without sensitizing EGFR and ALK alterations, adjuvant nivolumab does not appear to yield improvements in disease-free survival (DFS) when given after planned adjuvant chemotherapy and/or radiotherapy, according to a phase 3 study.

Procalcitonin a novel tumour biomarker for diagnosis, disease monitoring in FLC

A recent study has found procalcitonin to be a sensitive and specific serum biomarker for fibrolamellar carcinoma (FLC), making it a potential target for diagnosis and monitoring of treatment response.

Adjuvant atezolizumab plus bevacizumab falls short of improving RFS in high-risk HCC

An updated analysis of the IMbrave050 study reveals no sustained benefit on recurrence-free survival (RFS) among patients with high-risk hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab. Moreover, data on overall survival (OS) remains incomplete.

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

In the treatment of patients with unresectable embolization-eligible hepatocellular carcinoma (eeHCC), combining transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE (single tremelimumab regular interval durvalumab) regimen with or without lenvatinib substantially increases progression-free survival (PFS), as shown in the global phase 3 EMERALD-3 study.

DSC3-targeted immunotherapy shows promise in recurrent/metastatic HNSCC

Immunotherapy directed at desmocollin-3 (DSC3) safely improves outcomes in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) expressing DSC3, reports a study presented at ASCO 2026.

[Infographics] STRIDE vs atezolizumab + bevacizumab in 1L HCC – is there any difference in OS

Focusing on dual immunotherapy in unresectable HCC:

• STRIDE (single tremelimumab regular interval durvalumab) is the first and only IO regimen to date with 6-year OS data in unresectable HCC.¹

• In the HIMALAYA study, STRIDE was compared vs sorafenib and achieved a 1.9 times higher 6-year OS rate.¹

• Real-world data indicate that there are no significant differences between STRIDE and atezolizumab + bevacizumab as 1L therapies for advanced HCC, showing them to be equally valid options for patients with advanced HCC.²

Original New Drug Application Approvals by US FDA (1-15 May 2026)

New drug applications approved by US FDA as of 1-15 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC

In the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in China, the combination of ivonescimab plus chemotherapy significantly improves overall survival (OS) compared with tislelizumab plus chemotherapy, according to the phase III HARMONi-6 trial.